[{"data":1,"prerenderedAt":156},["ShallowReactive",2],{"drug-bicalutamide":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":35,"contraindications":58,"warnings":68,"renal":76,"monitoring":77,"interactions":78,"review":79,"examples":82,"atc":88,"iran":90,"usApproval":106,"links":112,"populations":128},"bicalutamide",1,{"fa":7,"en":8},"بیکالوتامید","Bicalutamide","antineoplastic-immunomodulating",{"fa":11,"en":12},"آنتی‌آندروژن","Antiandrogen",[14],{"name":15,"market":16},"Casodex","US",[18,19,7],"casodex","کازودکس",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-50","tablet","oral","50 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},50,"mg",false,[16],[32],{"source":33,"section":34},"fda-bicalutamide","How Supplied",[36],{"id":37,"disease":38,"label":39,"population":42,"type":46,"unit":28,"dose":47,"refs":48,"notes":51},"pc","prostate-cancer",{"fa":40,"en":41},"سرطان پروستات متاستاتیک (همراه آنالوگ LHRH) — ۵۰ mg یک بار در روز","Metastatic prostate cancer (with an LHRH analogue) — 50 mg once daily",{"minAge":43},{"value":44,"unit":45},18,"year","fixed",{"perDose":27,"dosesPerDay":5},[49],{"source":33,"section":50},"Dosage and Administration",[52],{"text":53,"refs":56},{"fa":54,"en":55},"هم‌زمان با شروع آنالوگ LHRH و هر روز در ساعت ثابت.","Start at the same time as the LHRH analogue; take at the same time each day.",[57],{"source":33,"section":50},[59],{"id":60,"severity":61,"text":62,"refs":65},"ci","block",{"fa":63,"en":64},"حساسیت به بیکالوتامید (آنژیوادم، کهیر)؛ زنان (اندیکاسیون ندارد)؛ بارداری (آسیب جنین).","Hypersensitivity to bicalutamide (angioedema, urticaria); women (no indication); pregnancy (fetal harm).",[66],{"source":33,"section":67},"Contraindications",[69],{"text":70,"refs":73},{"fa":71,"en":72},"آسیب کبدی (آزمایش کبد دوره‌ای)؛ ژنیکوماستی؛ افزایش اثر وارفارین.","Hepatitis (periodic liver tests); gynaecomastia; increased warfarin effect.",[74],{"source":33,"section":75},"Warnings",[],[],[],{"status":80,"reviewer":81,"date":81},"unverified",null,[83],{"regimen":37,"formulation":22,"input":84,"expect":87},{"ageYears":85,"weightKg":86},70,75,{"perDose":27,"tabletsPerDoseRounded":5},[89],"L02BB03",{"status":91,"forms":92,"refs":101},"registered",[93,97],{"code":94,"en":95,"fa":96},"07582","BICALUTAMIDE 150MG TAB","قرص بیکالوتامید ۱۵۰ میلی‌گرم",{"code":98,"en":99,"fa":100},"06765","BICALUTAMIDE 50MG TAB","قرص بیکالوتامید ۵۰ میلی‌گرم",[102],{"source":103,"section":104,"url":105},"darooyab-generic","G-954\u002FBicalutamide","https:\u002F\u002Fwww.darooyab.ir\u002FG-954\u002FBicalutamide",{"kind":107,"refs":108,"id":111},"NDA",[109],{"source":33,"section":110},"SPL approval \u002F marketing category","NDA020498",[113,116,120,123,126],{"kind":114,"url":115,"label":111},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=020498",{"kind":117,"url":118,"label":119},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=7a08d88b-051a-4c16-9560-12685c500c58","FDA Bicalutamide",{"kind":121,"url":122,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa697047.html",{"kind":124,"url":125,"label":89},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=L02BB03",{"kind":127,"url":105,"label":8},"darooyab",{"pregnancy":129,"pediatric":138,"geriatric":147},{"level":130,"text":131,"quote":134,"refs":135},"avoid",{"fa":132,"en":133},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Risk Summary Bicalutamide tablets are contraindicated for use in pregnant women because it can cause fetal harm.",[136],{"source":33,"section":137},"Precautions\u002FWarnings – Pregnancy",{"level":139,"text":140,"quote":143,"refs":144},"not-established",{"fa":141,"en":142},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","The safety and effectiveness of bicalutamide tablets in pediatric patients have not been established.",[145],{"source":33,"section":146},"Precautions\u002FWarnings – Pediatric Use",{"level":148,"text":149,"quote":152,"refs":153},"caution",{"fa":150,"en":151},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Hepatic Impairment Bicalutamide tablets should be used with caution in patients with moderate-to-severe hepatic impairment.",[154],{"source":33,"section":155},"Precautions\u002FWarnings – Geriatric Use",1792156164812]